2024
Modern Management of Gastric Neuroendocrine Neoplasms
Kunstman J, Nagar A, Gibson J, Kunz P. Modern Management of Gastric Neuroendocrine Neoplasms. Current Treatment Options In Oncology 2024, 25: 1137-1152. PMID: 39083164, DOI: 10.1007/s11864-024-01207-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsG-NENsGastrin-secreting tumorsSurgical resectionHeterogeneous group of tumorsProton pump inhibitor usageResection of visible lesionsG-NEN patientsGroup of tumorsRisk of progressionHigh-risk lesionsMetastatic diseaseNeuroendocrine tumorsNeuroendocrine neoplasmsMetastatic spreadEndoscopic resectionEndoscopic surveillanceTreatment paradigmInhibitor usageNeuroendocrine diseaseResectionTumorLow riskVisible lesionsHeterogeneous groupDe-escalation
2016
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Tang L, Basturk O, Sue J, Klimstra D. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. The American Journal Of Surgical Pathology 2016, 40: 1192-1202. PMID: 27259015, PMCID: PMC4988129, DOI: 10.1097/pas.0000000000000662.Peer-Reviewed Original ResearchConceptsHigh-grade pancreatic neuroendocrine neoplasmsAbnormal expression of p53PD-NECsWD-NETsPancreatic neuroendocrine neoplasmsNeuroendocrine neoplasmsExpression of p53Loss of DAXXNeuroendocrine carcinomaPoor-differentiated neuroendocrine carcinomasHigh-grade neuroendocrine neoplasmsAccurate diagnosisEvaluate immunohistochemical stainingG3 neuroendocrine neoplasmsHigh-grade progressionWHO grade 3Hematoxylin and eosin sectionsDisease-specific survivalAbnormal expressionGroup of tumorsDegree of diagnostic concordanceWHO classification schemeATRX protein expressionCoexisting adenocarcinomaAbnormal p53Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group†
Filosso PL, Yao X, Ruffini E, Ahmad U, Antonicelli A, Huang J, Guerrera F, Venuta F, van Raemdonck D, Travis W, Lucchi M, Rimner A, Thomas P, Weder W, Rocco G, Detterbeck F, Korst R. Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group†. European Journal Of Cardio-Thoracic Surgery 2016, 50: 766-771. PMID: 27032473, PMCID: PMC6279171, DOI: 10.1093/ejcts/ezw107.Peer-Reviewed Original ResearchConceptsNeuroendocrine thymic tumoursRecurrence-free survivalThymic carcinomaOverall survivalSurvival rateThymic tumorsThoracic surgeonsFive-year recurrence-free survivalWorld Health Organization histological classificationRetrospective multicentre cohort studyInternational Thymic Malignancy Interest GroupMedian overall survivalMulticentre cohort studyEuropean SocietyKaplan-Meier methodThymic epithelial tumorsLarge clinical seriesLog-rank testComparison of outcomesGroup of tumorsR0 resectionCohort studyPrognostic factorsNET patientsTC patients
2013
Gastroenteropancreatic neuroendocrine neoplasms: Historical context and current issues
Yang Z, Tang L, Klimstra D. Gastroenteropancreatic neuroendocrine neoplasms: Historical context and current issues. Seminars In Diagnostic Pathology 2013, 30: 186-196. PMID: 24144288, DOI: 10.1053/j.semdp.2013.06.005.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsProliferative rateDiverse group of tumorsWorld Health Organization classificationClassification of neuroendocrine tumorsGastroenteropancreatic neuroendocrine tumorsGroup of tumorsDigestive organsDiffuse neuroendocrine systemPrognostic parametersKi67 indexHistological gradeOrganization classificationPrognostic valueMitotic countClinical outcomesOptimal treatmentIntratumoral heterogeneityTNM stageTumorNeuroendocrine cellsGrading criteriaNeuroendocrine systemCut-pointsMultiple studies
2012
BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation
Virk RK, Van Dyke AL, Finkelstein A, Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML. BRAF V600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation. Modern Pathology 2012, 26: 62-70. PMID: 22918165, DOI: 10.1038/modpathol.2012.152.Peer-Reviewed Original ResearchConceptsPapillary thyroid microcarcinomaThyroid microcarcinomaPapillary thyroid carcinomaFollicular variantThyroid carcinomaLateral cervical node metastasesOsteoclastic-type giant cellsCervical node metastasisInfiltrative tumor borderGroup of tumorsBRAF V600E mutationClassic nuclear featuresGenotype-phenotype correlationStromal calcificationLymphovascular invasionNode metastasisClinicopathologic featuresLymphocytic infiltrationAggressive featuresTumor sizeCystic changesPapillary microcarcinomaAbsence of mutationsHigh prevalenceMicrocarcinoma
2010
Triple-negative breast cancer: disease entity or title of convenience?
Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews Clinical Oncology 2010, 7: 683-692. PMID: 20877296, DOI: 10.1038/nrclinonc.2010.154.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBRCA1 ProteinBreast NeoplasmsCarcinoma, Ductal, BreastCase ManagementCombined Modality TherapyDrug Resistance, NeoplasmFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, BRCA1Genes, erbB-2HumansMitotic IndexNeoplasm InvasivenessNeoplasm MetastasisNeoplasm ProteinsNeoplasm Recurrence, LocalPrognosisReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneConceptsTriple negative breast cancer tumorsNew systemic therapiesGood initial responseGroup of tumorsPoly (ADP-ribose) polymerase (PARP) inhibitorsBreast cancer tumorsHormonal therapySystemic therapyLuminal subtypeWorse prognosisClinical trialsDisease entityMTOR inhibitorsAngiogenesis inhibitorsPolymerase inhibitorsTherapeutic agentsCancer tumorsInitial responseTherapyTumorsInhibitorsSrc kinaseAgentsChemotherapyPatients
2000
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
Toyota M, Ohe-Toyota M, Ahuja N, Issa J. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 710-715. PMID: 10639144, PMCID: PMC15395, DOI: 10.1073/pnas.97.2.710.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaBase SequenceColorectal NeoplasmsCpG IslandsDNA MethylationDNA Mutational AnalysisDNA, NeoplasmGenes, p16Genes, p53Genes, rasHumansMicrosatellite RepeatsMutationPhenotypePoint MutationPolymorphism, Single-Stranded ConformationalProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSequence DeletionTumor Cells, CulturedConceptsCpG island methylator phenotypeColorectal cancerK-RAS mutationsDifferent genetic lesionsActivation of oncogenesTumor suppressor geneMultiple CpG islandsColorectal tumorsMethylator phenotypeCpG islandsDistinct genetic profilesP53 mutationsEpigenetic alterationsMolecular diversitySuppressor geneGenetic lesionsNovel pathwayGroup of tumorsGenetic alterationsK-RASMutationsCancer developmentSimultaneous methylationGenes
1999
Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype.
Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Research 1999, 59: 5438-42. PMID: 10554013.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAllelesCarrier ProteinsCpG IslandsCyclin-Dependent Kinase Inhibitor p16Gene Expression Regulation, NeoplasticHumansMethylationModels, GeneticMucous MembraneMutL Protein Homolog 1Neoplasm ProteinsNuclear ProteinsPhenotypePolymerase Chain ReactionStomach Neoplasms
1998
Electrophysiological Properties of Human Astrocytic Tumor Cells In Situ: Enigma of Spiking Glial Cells
Bordey A, Sontheimer H. Electrophysiological Properties of Human Astrocytic Tumor Cells In Situ: Enigma of Spiking Glial Cells. Journal Of Neurophysiology 1998, 79: 2782-2793. PMID: 9582244, DOI: 10.1152/jn.1998.79.5.2782.Peer-Reviewed Original ResearchMeSH KeywordsAction PotentialsAstrocytesAstrocytomaBrain NeoplasmsCarcinomaCell DifferentiationChildChoroid Plexus NeoplasmsDelayed Rectifier Potassium ChannelsHumansIon TransportNeoplasm ProteinsNeoplastic Stem CellsNerve Tissue ProteinsPatch-Clamp TechniquesPotassiumPotassium Channel BlockersPotassium ChannelsPotassium Channels, Inwardly RectifyingPotassium Channels, Voltage-GatedSodium Channel BlockersSodium ChannelsSpinal CordTetraethylammoniumTetrodotoxinConceptsAstrocytoma cellsTumor cellsGlial cellsWhole-cell patch-clamp recordingsCell patch-clamp recordingsAction potential-like responsesOlder pediatric patientsSpinal cord astrocytesHuman astrocytic tumor cellsSensitive sodium currentsGroup of tumorsLow-grade astrocytomasPatch-clamp recordingsOutward potassium currentGlial tumor cellsAstrocytic tumor cellsGeneration of spikesHigh input resistancePeritumoral astrocytesPediatric patientsMicroM Ba2Pilocytic astrocytomaPotassium currentAstrocytesElectrophysiological properties
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply